Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Focus on Fashion
Join us for the signature event of MS Focus: the Multiple Sclerosis Foundation, to be held at the...
Learn More
Advocacy
MS Focus on Fashion
Volunteer
Businesses
MS Research Trials
Supporter Program
Awareness Campaigns
Host an Event
Events
Awareness Month 2025
In this program we’ll navigate through the available treatment options and look at what the...
Learn more
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Healthcare Advisory Board
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
Health and Wellness Grant
The MS Focus Health and Wellness Program offers adaptive exercise and wellness education in safe,...
/Get-Help/MSF-Programs-Grants/Health-and-Wellness-Program
Shop
Privacy
Terms of Use
Site Map
Researchers: Fingolimod may help with secondary progressive MS
February 09, 2017
A research team led by scientists from Brigham and Women's Hospital found that Fingolimod interferes with signals sent by lipid receptors, and may reduce the disease-producing activities by cells in the nervous system. The findings suggest the treatment may hold promise for difficult-to-treat secondary progressive MS.
According to Francisco Quintana, a researcher in the Ann Romney Center for Neurologic Diseases, "One of the most important unmet clinical needs in MS is to design therapeutic approaches for the progressive phase of the disease, and a key unanswered question related to that is, what are the biological processes that drive disease pathogenesis at this stage?"
The study, published in PNAS and led by Quintana sheds new light on the role of sphingosine-1-phosphate, a type of lipid, and its receptors in SPMS. The researchers found that blockage of these signals with Fingolimod had important effects on astrocytes in both mice and humans, decreasing their proinflammatory and neurotoxic properties while also increasing the cells' anti-inflammatory capabilities.
The neuroprotective effects the team observed are not as strong as those they have recorded in previous studies of other drugs. The results suggest Fingolimod may help mitigate some aspects of SPMS in humans. A clinical trial of a highly related drug, led by Novartis, is now underway and encouraging preliminary results have been recently released.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more